Navigation Links
Isis Reports Financial Results and Highlights for First Quarter 2012
Date:5/8/2012

ata at the American Society of Clinical Oncology showing that treatment with OGX-427 produced a trend toward increased tumor cell death in patients with bladder cancer and preliminary Phase 2 data showing that treatment with OGX-427 decreased prostate specific antigen in patients with metastatic prostate cancer.
  • Xenon Pharmaceuticals selected a drug targeting the hepcidin-hemojuvelin pathway as a development candidate to treat anemia of inflammation, a common form of anemia.
  • Conference Call
    At 4:30 p.m. Eastern Time today, May 8, Isis will conduct a live webcast conference call to discuss this earnings release and related activities.  Interested parties may listen to the call by dialing 866-831-6162 and refer to passcode "ISIS 2012," or access the webcast at www.isispharm.com.  A webcast replay will be available for a limited time at the same address.

    About Isis Pharmaceuticals, Inc.
    Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

    Forward Looking Statements
    This press release includes forward-looking statements regarding Isis Pharmaceuticals' financial position and outlook, Isis' business, and the therapeutic and commercial potential of Isis' technologies and products in development, including the business of Regulus, Isis' jointly owned subsidiary.
    '/>"/>

    SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Vanda Pharmaceuticals Reports First Quarter 2012 Results
    2. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
    3. Halozyme Reports First Quarter 2012 Financial Results
    4. MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results
    5. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
    6. IRIDEX Reports 2012 First Quarter Results
    7. Cambrex Reports First Quarter 2012 Results
    8. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
    9. Cumberland Pharmaceuticals Reports First Quarter 2012 Financial Results
    10. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
    11. Neuland Labs Reports Financial Results For Fiscal Year 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... 2015  Mallinckrodt plc (NYSE: MNK ) announced ... share repurchase program. The open-ended authorization permits the company ... ordinary shares. "Funding additional initiatives and ... we continue to pursue a range of focused growth ...
    (Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
    (Date:1/22/2015)... MINNEAPOLIS, Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ... markets innovative proprietary products to treat voiding dysfunctions, today ... ended December 31, 2014.  Global revenue for the ... $4.4 million, a new quarterly revenue record, as compared ...
    Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
    ... THE WOODLANDS, Texas, Nov. 22, 2011 OncologyRx Care ... specialty pharmacy, has been selected by Incyte Corporation ...  pharmacies across the U.S. authorized to fill prescriptions for ... Myelofibrosis (MF) patients.   (Logo:  ...
    ... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ... Administration (FDA) has accepted for review the Company,s supplemental ... Use for the prevention of gout flares in patients ... Fee Act (PDUFA), the goal for a standard review ...
    Cached Medicine Technology:OncologyRx Care Advantage™ Chosen to Fill Prescriptions for Jakafi™ (ruxolitinib) 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 3Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 4Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 5Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 6Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 7Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 8
    (Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
    (Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
    (Date:1/22/2015)... Orlando, Florida (PRWEB) January 22, 2015 ... up today at the 2015 PGA Merchandise Show to ... lady and incredible female amateur golfer, Arlene McKitrick. The ... career female amateur golf tournament win. She won her ...
    (Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
    (Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
    Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
    ... HealthDay Reporter , TUESDAY, Dec. 14 (HealthDay ... years, especially women, are less likely to face the ... researchers say. But regular exercise while young only ... about 150 minutes of moderate to vigorous physical activity ...
    ... vaccines targeted against various types of cancer has raised ... however, is that these promising treatments are difficult to ... cellular target to stop cancer growth without inactivating the ... report a laboratory finding that has the potential to ...
    ... 14, 2010 Researchers at UT Southwestern Medical Center ... and normal tissue that predict survival time and potential ... "Patient responses to cancer treatment vary widely and ... Dr. David Mangelsdorf, chairman of pharmacology at UT Southwestern ...
    ... weapon against inoperable liver cancer is so tiny that ... to interventional radiologists at the Indiana University School of ... The glass spheres contain a radioactive element, yttrium-90, ... a very limited distance so that healthy tissue around ...
    ... Pallarito HealthDay Reporter , TUESDAY, Dec. 14 (HealthDay ... a key component of the new U.S. health-care reform law ... the first successful challenge to the controversial legislation. ... President Barack Obama and fellow Democrats against Republicans, will continue ...
    ... -- Scientists report that they have advanced their knowledge ... identifying 13 new potential variations. Tumors called pheochromocytomas ... the kidney. These tumors -- which are usually benign ... gland to produce too much adrenaline, resulting in high ...
    Cached Medicine News:Health News:Regular Exercise While Young May Slow Middle-Age Spread 2Health News:Regular Exercise While Young May Slow Middle-Age Spread 3Health News:UNC scientists discover potential strategy to improve cancer vaccines 2Health News:Gene information predicts survival time, possible new treatment options for lung-cancer patients 2Health News:Y-90 radioembolization offers promise for late-stage liver cancer 2Health News:Health-Care Reform Faces Long Legal Fight 2Health News:Health-Care Reform Faces Long Legal Fight 3Health News:Health-Care Reform Faces Long Legal Fight 4
    ... Eliminate the need for makeshift, modified nebulizer ... waste time gathering parts when your patient ... to deliver the utmost in Heliox rescue ... is fast becoming the standard of care ...
    ... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
    ... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
    ... as well as humidification, try Flo-Mist™., ... volume, continuous medication nebulizer (CMN), engineered to ... 200 ml reservoir and jet flow design ... nebulized medication delivery at 25 ml/hr. Particles ...
    Medicine Products: